Literature DB >> 6504329

The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas.

H Nakagawa, D Groothuis, R G Blasberg.   

Abstract

The RG-2 brain tumor model was used to determine whether unidirectional transport of alpha-aminoisobutyric acid (AIB) into brain and tumor tissue was increased after an intracarotid infusion of one of six different hypertonic solutions of L-arabinose. Intracarotid infusion of hypertonic solutions that have been reported as subthreshold for normal brain were used to determine whether they would selectively increase blood-to-tissue transport in brain tumors. No increase in the transport rate constant (K) across RG-2 tumor capillaries resulted from the infusion of 0.8- to 1.4-osm solutions. Infusions of 1.6- and 1.8-osm solutions were also performed, and blood-to-tissue transport was measured under conditions that produce maximum blood-brain-barrier disruption; however, no increase in the transport rate across tumor capillaries was measured. In brain regions surrounding the tumor, there was a trend toward increasing K values associated with increasing osmolality of the infusate, but the magnitude of this increase was small. There was a progressive increase in the K of tumor-free brain regions. This increase correlated with increasing osmolality of the infusate (0.8 to 1.8 osm). We conclude that intracarotid infusion of hypertonic solutions of L-arabinose does not increase the rate of delivery of water-soluble drugs to experimental RG-2 brain tumors. In this situation, the use of hypertonic infusions may be counterproductive and result in a greater delivery to and exposure of surrounding and normal brain tissue to levels of chemotherapeutic drugs which are potentially neurotoxic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6504329     DOI: 10.1212/wnl.34.12.1571

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 2.  Blood-brain barrier and new approaches to brain drug delivery.

Authors:  W M Pardridge; R J Boado; K L Black; P A Cancilla
Journal:  West J Med       Date:  1992-03

Review 3.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

4.  Chemotherapy in experimental brain tumor, part 2: pretreatment with leukotriene C4 prolongs survival.

Authors:  P Black; C M Hand; J R Vender; S D Finkelstein
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Vascular permeability and cell kinetics of ethylnitrosourea (ENU)-induced rat brain tumours.

Authors:  T Inoue; T Tashima; S Nishio; I Takeshita; T Iwaki; M Fukui
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

7.  Intra-arterial mannitol infusion in the chemotherapy for malignant brain tumors.

Authors:  Y Iwadate; H Namba; T Saegusa; K Sueyoshi
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

8.  A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.

Authors:  Mateusz Pinkiewicz; Milosz Pinkiewicz; Jerzy Walecki; Michał Zawadzki
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.